



PDL Drug Class Review Announcement July 10, 2012

Drug Classes to be Reviewed:

Oral bisphosphonates, Biguanides, Hypoglycemic combinations, Meglitinides, Newer diabetic agents, Erythropoiesis stimulating agents, Overactive bladder agents, Protease Inhibitors for Hepatitis C and the Stimulant/ADHD drugs. The medications listed below and all of their respective formulations, dosage forms, and strengths will be reviewed.

Request for Dossier:

Submit a dossier by June 18, 2012 for clinical review at the Pharmacy and Therapeutics Committee meeting on July 10, 2012. Include a brief synopsis of the clinical information, one to four pages in length, for P&T dissemination. **If a dossier has been previously submitted, only submit a synopsis of the clinical information unless new information is available.**

Mail, fax, or email dossier and synopsis to:
Department of Health Care Policy & Financing
1570 Grant Street
Denver, CO 80203
Attn: Robert Lodge
Fax: 303-866-3590
robert.lodge@state.co.us

Request for Supplemental Rebate Offers:

Submit two copies of executed supplemental rebate agreements by July 5, 2012. The supplemental rebate agreement template is posted on the PDL webpage. All fields highlighted in gray must be completed on the template. The performance period for these agreements is **October 1, 2012 – September 30, 2013**. Please use a **separate Attachment A (Net Cost Offer) for combination products**.

Mail offers to:
Department of Health Care Policy & Financing
1570 Grant Street
Denver, CO 80203
Attn: Robert Lodge

Pharmacy & Therapeutics (P&T) Committee Meeting:

The P&T Committee will review clinical data and will receive public comments and testimony related to the drug classes being reviewed. They will then make a clinical recommendation concerning these medications. The P&T Committee meeting will be held on July 10, 2012, from 1:00 p.m. - 5:00 p.m. at 225 E. 16th Avenue, Denver, Colorado, first floor conference room.

Public Comments:

Public comments concerning the drugs subject to review need to be submitted by July 6, 2012. The P&T Committee will review public comments before the meeting.

Email comments to: pdl@state.co.us

or

Mail comments to:

Colorado Department of Health Care Policy and Financing
Pharmacy Benefits Section
1570 Grant Street
Denver, CO 80203
Attn: Robert Lodge

Drugs Subject to Review:**Oral Bisphosphonates**

Brand Name	Generic Name
ACTONEL	risedronate
ACTONEL w/ CALCIUM	risedronate w/ calcium
ATELVIA	risedronate ER
BINOSTO	alendronate effervescent
BONIVA	ibandronate
	ibandronate
FOSAMAX	alendronate
FOSAMAX w/ D	alendronate w/ D
	alendronate
DIDRONEL	etidronate
	etidronate
SKELID	tiludronate

Biguanides

Brand Name	Generic Name
FORTAMET	metformin ER
GLUCOPHAGE	metformin
GLUCOPHAGE XR	metformin ER
GLUMETZA	metformin ER
RIOMET	metformin
	metformin
	metformin ER

Hypoglycemic Combinations

Brand Name	Generic Name
ACTOPLUS MET	pioglitazone/metformin
AVANDAMET	rosiglitazone/metformin
AVANDARYL	rosiglitazone/glimepiride
DUETACT	pioglitazone/glimepiride
GLUCOVANCE	glyburide/metformin

	glyburide/metformin
JANUMET	sitagliptin/metformin
JANUMET XR	sitagliptin/metformin
JENTADUETO	linagliptin/metformin
JUVISYNC	sitagliptin/simvastatin
KOMBIGLYZE	saxagliptin/metformin
METAGLIP	glipizide/metformin
	glipizide/metformin
PRANDIMET	repaglinide/metformin

Meglitinides

Brand Name	Generic Name
PRANDIN	repaglinide
STARLIX	nateglinide

Thiazolidinediones

Brand Name	Generic Name
ACTOS	pioglitazone
AVANDIA	rosiglitazone

Newer Diabetic Agents

Brand Name	Generic Name
SYMLIN	pramlintide
BYDUREON	exenatide
BYETTA	exenatide
JANUVIA	sitagliptin
ONGLYZA	saxagliptin
TRADJENTA	linagliptin
VICTOZA	liraglutide

Erythropoiesis Stimulating Agents

Brand Name	Generic Name
ARANESP	darbepoetin alfa
EPOGEN	epoetin alfa
OMONTYS	peginesatide
PROCRIT	epoetin alfa

Overactive Bladder Agents

Brand Name	Generic Name
DETROL	tolterodine
DETROL LA	tolterodine ER
DITROPAN	oxybutynin
	oxybutynin
DITROPAN XL	oxybutynin ER
	oxybutynin ER
ENABLEX	darifenacin

	flavoxate
GELNIQUE	oxybutynin gel
OXYTROL	oxybutynin patch
SANCTURA	trospium
SANCTURA XL	trospium ER
TOVIAZ	fesoterodine ER
VISICARE	solifenacin

Protease Inhibitors for Hepatitis C

Brand Name	Generic Name
INCIVEK	telaprevir
VICTRELIS	boceprevir

*When submitting supplemental rebate agreements, keep in mind that they will not affect the current PA criteria imposed on this class of medications.

Stimulants and ADHD Drugs

Brand Name	Generic Name
ADDERALL	mixed amphetamine salts
	mixed amphetamine salts
ADDERALL XR	mixed amphetamine salts ER
	mixed amphetamine salts ER
CONCERTA	methylphenidate ER
	methylphenidate ER
DAYTRANA	methylphenidate transdermal
DESOXYN	methamphetamine
FOCALIN	dexmethylphenidate
FOCALIN XR	dexmethylphenidate
INTUNIV	guanfacine ER
KAPVAY	clonidine ER
METADATE CD	methylphenidate ER
METADATE ER	methylphenidate ER
METHYLIN SUSPENSION	methylphenidate
NUVIGIL	armodafinil
PROVIGIL	modafinil
RITALIN	methylphenidate
STRATTERA	atomoxetine
VYVANSE	lisdexamfetamine